[go: up one dir, main page]

AR070649A1 - Derivados de 1,3- dihidro -isoindol - Google Patents

Derivados de 1,3- dihidro -isoindol

Info

Publication number
AR070649A1
AR070649A1 ARP080103758A ARP080103758A AR070649A1 AR 070649 A1 AR070649 A1 AR 070649A1 AR P080103758 A ARP080103758 A AR P080103758A AR P080103758 A ARP080103758 A AR P080103758A AR 070649 A1 AR070649 A1 AR 070649A1
Authority
AR
Argentina
Prior art keywords
hal
atoms
replaced
mono
nr6conr6r7
Prior art date
Application number
ARP080103758A
Other languages
English (en)
Inventor
Hans-Michael Eggenweiler
Christian Sirrenberg
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR070649A1 publication Critical patent/AR070649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Los derivados de 1,3-dihidro-isoindol de la formula (1) en donde R1 es A; R2 es A, (CH2)nAr o (CH2)nHet; R1 y R2 son, junto con el átomo de N al que están unidos, isoindolilo; R3 es H, Hal, OH, CN, NO2, C(O)H, NH2, COOH, COOA, CsCH, CsC-CH2OH, CONH2, CONHA, CONAA', SO2NH2, NHCONH2, X-A, X-(CH2)nAr o X-(CH2)nHet, en donde X es un enlace, -O-, -CO-, -CO2-, -C(O)NH, -C(O)NA', -S-, -SO-, -SO2-, SO2NH-, -SO2NA', -NH-, -NA'-, -NHSO2-, -NA'SO2, -NHCO-, -NA'CO-, -NHCONH- o -NA'CONH-; R3' es H, A, Hal, OA o CN; A, A' son en cada caso, de modo independiente entre sí, alquilo no ramificado o ramificado C1-10, en donde uno, dos o tres grupos CH2 o CH no adyacentes pueden estar reemplazados por O, S, SO, SO2, CO, NH, NR5 y/o por grupos -CH=CH y/o también 1-5 átomos de H pueden estar reemplazados por F, Cl, Br y/o R4, o cicloalquilo C3-7, A y A' son, junto con el átomo de N al que están unidos, también un heterociclo monocíclico saturado no sustituido o mono-, di- o trisustituido con Hal, A, (CH2)nOH, (CH2)nOA y/u =O (oxígeno del carbonilo), que puede contener otros 1 a 3 átomos de N, O y/o S; R4 es COOR6, CN, CONR6R7, NR6R7, NHCOR6, NHCOOR6, NR6CONR6R7 u OR6; R5 es cicloalquilo C3-7, cicloalquilalquileno C4-10, Alk o alquilo no ramificado o ramificado C1-6, en donde uno, dos o tres grupos CH2 o CH no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH y/o también 1-5 átomos de H pueden estar reemplazados por F y/o Cl; R6, R7 son en cada caso, de modo independiente entre sí, H o alquilo C1-5, en donde 1-3 grupos CH2 o CH no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH, NMe o Net y/o también 1-5 átomos de H pueden estar reemplazados por F y/o Cl, R6 y R7 son juntos también una cadena de alquileno con 2, 3, 4, 5 o 6 átomos de C, en donde 1-3 átomos de C no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH, NR5, NCOR5 o NCOOR5; Alk es alquenilo C2-6; Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di-, tri-, tetra o pentasustituido con Hal, A, (CH2)nCN, (CH2)nAr', (CH2)nHet', (CH2)nOA, (CH2)nOH, S(O)mA, NO2, (CH2)NR6R7, NR5R6, CONR6R7 CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7 y/o NR6SO2R7; Ar' es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Hal, A, CN, fenilo, OA, OH, S(O)mA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7 y/o NR6SO2R7; Het es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, CN, Ar', Het' OA, OH, S(O)mA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7, NR6SO2R7, =S, =NR8, =NR8R4 y/u =O (oxígeno del carbonilo); Het' es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, CN, Ar', OA, OH, S(O)nA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7, NR6SO2R7, =S, =NR8, =NR8R4 y/u =O (oxígeno del carbonilo); R8 es H o A; Hal es F, Cl, Br o I; m es 0, 1 o 2, n 0, 1, 2, 3 o 4; así como sus derivados, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de la HSP90 y pueden ser utilizados para preparar un medicamento para el tratamiento de enfermedades en las que la inhibicion, la regulacion y/o la modulacion de la HSP90 desempena un papel importante.
ARP080103758A 2007-08-30 2008-08-29 Derivados de 1,3- dihidro -isoindol AR070649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007041116A DE102007041116A1 (de) 2007-08-30 2007-08-30 1,3-Dihydro-isoindolderivate

Publications (1)

Publication Number Publication Date
AR070649A1 true AR070649A1 (es) 2010-04-28

Family

ID=40029128

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103758A AR070649A1 (es) 2007-08-30 2008-08-29 Derivados de 1,3- dihidro -isoindol

Country Status (16)

Country Link
US (1) US8183279B2 (es)
EP (1) EP2181092B1 (es)
JP (1) JP5529739B2 (es)
KR (1) KR20100061817A (es)
CN (1) CN101790513A (es)
AR (1) AR070649A1 (es)
AU (1) AU2008295176B2 (es)
BR (1) BRPI0815059A2 (es)
CA (1) CA2697934C (es)
DE (1) DE102007041116A1 (es)
EA (1) EA201000362A1 (es)
ES (1) ES2532853T3 (es)
IL (1) IL204126A (es)
MX (1) MX2010002042A (es)
WO (1) WO2009030316A1 (es)
ZA (1) ZA201002217B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
MX2014014188A (es) 2012-05-25 2015-05-11 Berg Llc Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta.
HK1217649A1 (zh) * 2012-12-27 2017-01-20 德雷克塞尔大学 針對hbv感染的新型抗病毒劑
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
SG11201610746SA (en) * 2014-07-08 2017-01-27 Viiv Healthcare Uk Ltd Isoindoline derivatives for use in the treatment of a viral infection
US10316167B2 (en) 2014-09-19 2019-06-11 Plastipak Packaging Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
US10464907B2 (en) * 2016-01-29 2019-11-05 Industry Academic Cooperation Foundation Keimyung University Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof
EP3478686B1 (en) 2016-06-29 2020-04-15 H. Hoffnabb-La Roche Ag Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN106366089B (zh) * 2016-08-19 2019-06-11 爱斯特（成都）生物制药股份有限公司 二氢异吲哚衍生物及其类似物的制备方法
WO2018132769A1 (en) 2017-01-12 2018-07-19 University Of Kansas Hsp90b n-terminal isoform-selective inhibitors
EP4573087A1 (en) * 2022-08-21 2025-06-25 University of Notre Dame du Lac Use of (isoindolin-2-yl)(4-hydroxy-3-(isoindoline-2-carbonyl)phenyl)methanones in the treatment of tumor necrosis factor receptor-associated protein 1 dysfunction
CN117402075B (zh) * 2023-10-17 2026-01-09 厦门大学深圳研究院 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
CA2367108A1 (en) 1999-03-12 2000-09-14 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Method of inhibiting a chaperone protein
EP1265913A4 (en) 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF THE INTERACTION BETWEEN GRP94 AND A LIGAND, AND CLEANING, SCREENING AND THERAPEUTIC PROCEDURES RELATING TO IT
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
EP1322325A4 (en) 2000-07-20 2004-09-15 Merck & Co Inc INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CA2440842A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
BRPI0513819A (pt) 2004-07-27 2008-05-20 Novartis Ag inibidores de hsp90
WO2006109075A2 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
CA2605985A1 (en) 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds

Also Published As

Publication number Publication date
JP2010536893A (ja) 2010-12-02
MX2010002042A (es) 2010-03-15
EP2181092B1 (de) 2015-01-14
CN101790513A (zh) 2010-07-28
CA2697934C (en) 2016-02-16
AU2008295176A1 (en) 2009-03-12
JP5529739B2 (ja) 2014-06-25
AU2008295176B2 (en) 2013-05-02
US20100311745A1 (en) 2010-12-09
EP2181092A1 (de) 2010-05-05
IL204126A (en) 2015-07-30
WO2009030316A1 (de) 2009-03-12
KR20100061817A (ko) 2010-06-09
US8183279B2 (en) 2012-05-22
ZA201002217B (en) 2017-11-29
CA2697934A1 (en) 2009-03-12
DE102007041116A1 (de) 2009-03-05
EA201000362A1 (ru) 2010-08-30
ES2532853T3 (es) 2015-04-01
BRPI0815059A2 (pt) 2015-02-10

Similar Documents

Publication Publication Date Title
AR070649A1 (es) Derivados de 1,3- dihidro -isoindol
AR067506A1 (es) Derivados de quinazolinamida
AR061735A1 (es) Derivados de indazol, composiciones farmaceuticas y uso de los mismos
AR067082A1 (es) Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales.
AR061009A1 (es) 1,2-difenil-pirazoles i i como inhibidores de hsp90
AR074418A1 (es) Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores
AR061010A1 (es) Derivados de triazol i i
AR054047A1 (es) Derivados de fenilquinazolina
AR090602A1 (es) AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR074493A1 (es) Derivados de quinazolinamida
AR052482A1 (es) Derivados de triazol como inhibidores de hsp90
AR073055A1 (es) Derivados biciclicos de triazol
AR082726A1 (es) Derivados de triazolopirazina
AR078979A1 (es) Derivados de triciclo pirazol amina
AR082722A1 (es) Derivados de pirimidina
AR080803A1 (es) Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias.
AR072098A1 (es) Derivados de pirrolidina como inhibidores de metap-2
AR078313A1 (es) Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras
AR066892A1 (es) Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit
AR072148A1 (es) Derivados de quinoxalindiona
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR072192A1 (es) Derivados de tiazolil-piperidina
AR077488A1 (es) Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales.

Legal Events

Date Code Title Description
FB Suspension of granting procedure